ABAndrés Felipe Bejarano-Ramirez

Andrés Felipe Bejarano-Ramirez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrés Felipe Bejarano-Ramirez has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Air pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort

    by Mateo Tamayo, Nicolás Duque-Clavijo, Astrid Berena Herrera-López, Manuela Estrada-Schweineberg, Andres Felipe Bejarano, Juliana Pardo-Aljure, Laura Baldovino-Chiquillo, David Uscategui-López, Sebastián Dueñas-Hernández, María Paula Molina, et al.

    Background: Lung cancer remains a critical global health concern, with a substantial fraction arising in never-smokers. Air pollution—including particulate matter (PM2.5, PM10), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3)—has been implicated in lung carcinogenesis; however, studies linking these exposures to molecular biomarkers in Hispanic populations remain scarce. This study aimed to evaluate the association between exposure to air pollutants and oncogenic mutations in non-small cell lung cancer (NSCLC) in Hispanic patients in Bogotá. Methods: A retrospective cohort study was conducted on 205 Hispanic patients diagnosed with NSCLC between 2015 and 2022 at a quaternary care hospital in Bogotá, Colombia. Lung cancer driver mutations [epidermal growth factor receptor mutations (EGFRm), anaplastic lymphoma kinase (ALK) rearrangement, and programmed death-ligand 1 (PD-L1) expression] were assessed by reverse transcription polymerase chain reaction and immunohistochemistry. The estimated individual-level exposure to air pollutants (PM2.5, PM10, NO2, SO2, O3, and CO) was assessed from Bogotá’s Air Monitoring Stations using an inverse distance weighted regression model. Adjusted logistic regression analyses evaluated associations between biomarkers and pollutants. Kaplan-Meier and Cox proportional hazards models examined survival outcomes. Results: Mean annual exposure to PM2.5 (15.9 µg/m3), PM10 (32.6 µg/m3), and NO2 (28.3 µg/m3) exceeded the thresholds recommended by the World Health Organization. EGFRm were identified in 24.9% of patients, ALK rearrangements in 12.2%, and PD-L1 expression ≥1% in 41.5% (≥50% in 5.4%). EGFRm was associated with increased exposure to PM2.5 and PM10 levels [PM2.5: odds ratio (OR) 2.49, 95% confidence interval (CI): 1.11–6.41; PM10: OR 1.54, 95% CI: 1.05–2.34]. NO2 was associated with increased PD-L1 expression (OR 1.83, 95% CI: 1.33–2.65). The 5-year overall survival (OS) rate was 29.0%. Increased exposure to PM2.5 [hazard ratio (HR) 1.72; 95% CI: 1.04–2.84] and SO2 (HR 1.69, 95% CI: 1.07–2.68) were associated with mortality. Conclusions: These results underscore the potential impact of air pollution on the molecular landscape and clinical outcomes of patients diagnosed with NSCLC, and they open new avenues for research in genetically admixed populations.


  • Open Access

    Advanced Hepatocellular Carcinoma: Benefits of Atezolizumab and Bevacizumab in Clinical Practice. Case Report

    by Erick Andrés Cantor Rizo, Andrés Felipe Bejarano Ramírez, Zamira Fernanda Gómez Giraldo, John Alejandro Murillo Silva, Henry Alexander Vargas Díaz, Mónica Lorena Tapias Mantilla

    Background: Hepatocellular carcinoma (HCC), originating from hepatocytes, ranks as the sixth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Treatment options include surgical resection, locoregional therapies, systemic therapy, and liver transplantation, depending on disease stage. Case report: We describe a 78-year-old male with multiple comorbidities diagnosed with stage IIIB hepatocellular carcinoma according to the BCLC B classification. He was treated with atezolizumab and bevacizumab, achieving a favorable response with tumor marker negativization and stable disease. Discussion: Since 2008, HCC treatment has undergone substantial progress. Earlier systemic therapies such as sorafenib and lenvatinib offered response rates around 24% and overall survival of up to 13 months. Current therapies have demonstrated significantly improved outcomes. Notably, the phase III IMbrave150 trial (2020) showed the advantages of combining immunotherapy with antiangiogenic agents over sorafenib in patients with advanced HCC, with overall survival reaching up to 89%.

  • Open Access

    PD-L1 expression in gastric cancer assessed with antibodies 28-8 and 22C3

    by Erick Andrés Cantor, Andrés Felipe Bejarano-Ramírez, Laura Chacón Zambrano, Iván Camilo Triana, Henry Alexander Vargas, Javier Mauricio Segovia, Luis Eduardo Pino, John Alejandro Murillo, Roció López

    Programmed cell death ligand 1 (PD-L1) has emerged as a key biomarker in determining both the progression and prognosis of gastric cancer (GC). Consequently, its detection through immunohistochemical (IHC) analysis is essential for guiding appropriate treatment selection. We conducted an analytical, observational study based on a five-year retrospective cohort of patients diagnosed with gastric cancer at a comprehensive oncology center in Colombia. All patients underwent immunohistochemistry (IHC) to assess PD-L1 expression and calculate the Combined Positive Score (CPS). The objective of this study was to compare the positivity detection rates between the 28-8 and 22C3 assays and to evaluate the concordance between them. A descriptive analysis of clinical and pathological variables was performed. Univariate analysis was used to determine the frequency of PD-L1 expression and CPS distribution. Kaplan-Meier survival analysis was applied and stratified by PD-L1 status. Concordance between the two assays was assessed using the kappa (κ) index. A total of 175 patients diagnosed with gastric cancer (GC) and tested for PD-L1 expression were included in the study. Complete pathological and IHC data were available for 155 patients. Among them, 39.4% were tested with the 28-8 assay, and 60.6% with the 22C3 assay. PD-L1 positivity was observed in 34.4% of cases using the 28-8 assay and in 28.7% using the 22C3 assay. Among patients with available follow-up data (n = 34), PD-L1 testing was performed using the 22C3 clone, with a positivity rate of 35.3%. In the subgroup analysis of patients tested with both antibodies (n = 20), 60% were PD-L1 positive. Within this subset, 25% had a CPS of 1-4, 16.7% had a CPS of 5-9, and 58.3% had a CPS ≥ 10. For the 22C3 assay specifically, PD-L1 positivity was observed in 40% of cases, with 37.5% having a CPS of 1-4 and 62.5% a CPS ≥ 10; notably, no cases in this group had a CPS of 5-9. The concordance rate between the 28-8 and 22C3 assays was 61%, as measured by the kappa index. The 28-8 clone identified a higher proportion of patients with PD-L1 expression compared to the 22C3 antibody. However, both assays demonstrated a concordance rate of 61%. In the study population, the subgroup with a Combined Positive Score (CPS) ≥ 10 was the most prevalent, suggesting that high PD-L1 expression is relatively common and potentially clinically relevant in this cohort.


  • Open Access

    Nueva era en el abordaje del adenocarcinoma de pulmón estadio temprano: estudio observacional con seguimiento de 3 años

    by Ivan Triana, Isabel Hernández-Linares, Angela Aguirre, Jairo Hildebrando Roa, Olga Milena García, Javier Mauricio Segovia, Erick Cantor, Andrés Felipe Bejarano-Ramirez, Henry Vargas, Luis Eduardo Pino, et al.

    Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.

  • Open Access

    Respuesta profunda y duradera en cáncer de pulmón con mutación L718Q en EGFR, adquirida después de la terapia con osimertinib

    by Juan Manuel Vásquez-Jiménez, Andres Felipe Bejarano Ramirez, Erick Andres Cantor Rizo, Luis Eduardo Pino

    Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).

  • Olaparib-Induced Cutaneous Vasculitis in a Patient with Ovarian Cancer: A Case Report and Literature Review

    by Juliana Cantor-Niño, Nicolás Duque-Clavijo, Andrés Felipe Bejarano-Ramirez, Henry Vargas, Javier Mauricio Segovia, Luis Eduardo Pino, Erick Cantor


  • Undifferentiated sarcoma arising from fibrous dysplasia in a young adult

    by Erick Andrés Cantor, Javier Mauricio Segovia, Sergio Osorio, John Alejandro Murillo Silva, Henry Alexander Vargas, Luis Eduardo Pino, Iván Camilo Triana, Angelica Carolina Sáenz, Pablo Arbeláez Echeverri, Andres Felipe Bejarano